NEW YORK (GenomeWeb) – VolitionRx announced today that it has received CE marking for its blood-based colorectal cancer assay NuQX001S, one of several assays the company intends to market together for cancer diagnosis.

The test is based on the company's Nucleosomics technology platform, which identifies and measures nucleosomes in the bloodstream. VolitionRx is developing a suite of NuQ ELISA assays and said that it aims to commercialize a test comprising four to six individual assays for clinical use in Europe next year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.